Biohaven Pharmaceutical Holding Co Ltd

Stock Chart, Company Information, and Scan Results

$9.61(as of Apr 28, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Biohaven Pharmaceutical Holding Co Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$9.61
Ticker SymbolBHVN
ExchangeNyse
SectorHealthcare
IndustryBiotechnology
Employees274
CountyUSA
Market Cap$1,442.5M
EBIDTA-698.4M
10-Day Moving Average10.27
P/E Ratio-1.56
20-Day Moving Average9.87
Forward P/E Ratio0.00
50-Day Moving Average10.03
Earnings per Share-6.86
200-Day Moving Average12.33
Profit Margin-Infinity%
RSI46.60
Shares Outstanding150.4M
ATR0.69
52-Week High24.06
Volume1,167,762
52-Week Low7.48
Most Recent Support Level9.51
Book Value52.1M
Most Recent Resistance Level10.97
P/B Ratio22.18
Upper Keltner11.43
P/S RatioInfinity
Lower Keltner8.31
Debt-to-Equity Ratio11.43
Next Earnings Date05/08/2026
Cash Surplus114.0M
Next Ex-Dividend DateUnknown

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Pharmaceutical Holding Co Ltd In Our Stock Scanner

As of Apr 29, 2026
example chart graphic
Scan Name: Discounted Stocks with Earnings GrowthScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Gravestone DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.